Registration for a live webinar on 'Phasing Out Animal Testing: A New Era for Pharmaceutical Innovation' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Epidemiology and Risk Factors
-
1. Coronary heart disease epidemiology: global context for a new genetic understanding
- Prof. Harry Hemingway
-
2. Cardiovascular risk factors
- Dr. Michal Vrablik
-
3. Lipoproteins
- Prof. Arnold von Eckardstein
-
4. Thrombotic risk factors for cardiovascular disease
- Prof. Gordon Lowe
-
5. Lipoprotein(a)
- Dr. Jaimini Cegla
- Biology of Coronary Heart Disease
-
6. Plaque rupture
- Prof. Petri Kovanen
-
7. Transcription factors and complex disease development
- Dr. Ines Pineda-Torra
-
8. Animal models to explore cardiovascular disease
- Prof. Martin Merkel
- Treatment
-
9. Diagnosis and treatment of dyslipidemias
- Prof. Anton Stalenhoef
-
10. Key drug discovery challenges in cardiovascular medicine
- Dr. Dan Swerdlow
- Dr. Michael V. Holmes
- Genetics
-
11. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
12. Heart disease genes and SNPs
- Prof. Steve Humphries
-
13. Familial hypercholesterolaemia: genetic causes and treatment
- Prof. Steve Humphries
-
14. Familial hypercholesterolaemia: cascade testing and monogenic vs. polygenic causes
- Prof. Steve Humphries
-
16. Genetics of cardiovascular disease
- Prof. Philippa Talmud
-
17. The genetics of CHD: moving research findings into patient benefit
- Prof. Steve Humphries
-
19. The genetics of abdominal aortic aneurysm
- Dr. Seamus Harrison
-
20. Genome scans for hypertension
- Prof. Patricia Munroe
-
21. Telomeres and cardiovascular disease
- Dr. Jess Buxton
-
23. Genetics of hypertrophic cardiomyopathy (HCM)
- Dr. Petros Syrris
- Archived Lectures *These may not cover the latest advances in the field
-
24. Gene-environment interaction and oxidative stress in cardiovascular disease
- Dr. Jeffrey Stephens
-
25. Gene therapy as a therapeutic option for lipoprotein lipase deficiency
- Dr. Jan Albert Kuivenhoven
-
26. Cardiovascular diseases: from epidemiology to nutritional interventions
- Dr. Antonis Zampelas
-
27. Genetic testing for CHD risk: fact or fiction?
- Prof. Steve Humphries
-
28. Pharmacogenetics: progress, pitfalls and clinical potential
- Prof. Steve Humphries
-
29. Familial hyperchlolesterolaemia: a monogenic cause of early CHD
- Prof. Steve Humphries
-
30. Lipid metabolism
- Dr. Ulrike Beisiegel
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- What are the conventional risk factors for CHD
- The multifactorial nature of CAD
- Gene:environment interaction and risk of CAD
- Identifying gene:environment interaction
- The basis for gene:environment interactions
- Measurement of genetic and environmental factors
- What is gene environment interaction
- How to test for gene:environment interaction (1)
- How to test for gene:environment interaction (2)
- Prospective vs. case:control studies
- Candidate gene approach
- Examples of the candidate gene approach
- Northwick park heart study II
- APOE, smoking and CHD risk
- Role of ApoE and LPL in fat metabolism
- CHD risk by APOE genotype and smoking
- Can we replicate these results in another study?
- APOE E4 effect in smokers and non smokers
- APOE smoking and CHD risk mechanisms
- LPL: smoking interaction and CHD risk
- What is lipoprotein lipase and what does it do?
- Lipoprotein lipase function 1: hydrolysis
- Lipoprotein lipase function 2: bridging
- Common LPL variants
- Why are raised triglycerides a risk factor?
- LPL - a good candidate gene
- D9N, N291S: TG levels and risk of heart disease
- LPL:smoking interaction on HD risk
- Survival plot for LPL-D9N and smoking, NPHSII
- The mechanism for the LPL-D9N effect on risk
- The LPL-D9 and LPL-N9 bridging function test (1)
- The LPL-D9 and LPL-N9 bridging function test (2)
- Can we visualise the binding at 4 degrees?
- Mechanisms for LPL-N9:smoking interaction
- Nature and nurture
- Genome wide association scans
- Illumina and Affymetix CHIPs
- Results from the GWASs for CHD
- SNPSs that have been identified from GWAS
- Back to where we started
- Conclusion
Topics Covered
- Conventional CVHD risk factors
- Multifactorial nature of CVD
- Gene-environment interaction and how to test for it
- Candidate gene approach to CVD genetics vs. genome-wide scans
- Examples of the candidate gene approach and gene-environment interaction, APOE and smoking interaction, LPL and smoking
- Mechanisms for these effects
- Novel genes identified by genome-wide scans for CHD and lipid traits
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Talmud, P. (2008, November 24). Genetics of cardiovascular disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved March 20, 2025, from https://doi.org/10.69645/MBQC1651.Export Citation (RIS)
Publication History
- Published on November 24, 2008
Financial Disclosures
- Prof. Philippa Talmud has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.